There are 412 resources available
1328P - Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib
Presenter: Meredith LaRose
Session: Poster session 19
1455P - Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Presenter: Maurice Pérol
Session: Poster session 20
1302P - Treatment outcomes and safety of durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in Thai populations: A real-world, multi-center observational study
Presenter: Piyada Sitthideatphaiboon
Session: Poster session 04
1292MO - A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or elderly (≧75 years): NEJ039A
Presenter: Ryo Ko
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
176P - Enhancing immunotherapy response prediction via multimodal integration of radiology and pathology deep learning models
Presenter: Marta Ligero
Session: Poster session 01
1450P - Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
Presenter: Matthieu Roulleaux Dugage
Session: Poster session 20
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
1719P - Decentralized clinical trials: Is there a space in Italy?
Presenter: Celeste Cagnazzo
Session: Poster session 23
2294P - Whole genome sequencing to define the germline-somatic interaction in young-onset lung cancer
Presenter: Jaclyn LoPiccolo
Session: Poster session 08
661MO - Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation
Presenter: Tae Won Kim
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast